Application of parabacteroides faecalis in preparation of medicine for separating graft anti-leukemia effect and graft-versus-host disease

By using Parabacteroidetes fecal (P.merdae) as a single strain, the balance of GVHD and graft anti-leukemia effects after allogeneic hematopoietic stem cell transplantation was solved, significantly improved the symptoms of GVHD and survival after transplantation, and enhanced graft resistance The effect of leukemia provides a safe and efficient treatment plan.

CN119055685AInactive Publication Date: 2024-12-03NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Patent Information

Application Number
CN202411286553.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

After the transplantation of allogeneic hematopoietic stem cells for the treatment of malignant hematopoietic tumors, the graft anti-leukemia effect and graft-versus-host disease (GVHD) is a complex and severe immune response, especially the treatment of intestinal GVHD lacks effective solutions and inhibits the treatment of GVHD may weaken the anti-leukemia effect of the graft and increase the risk of recurrence of hematologic malignant tumors.

Method used

Parabacteroides merdae, P.merdae, was used as a single strain, and was cultured and standardized in vitro and treated with standardized treatment. It was used to prepare drugs for isolating graft anti-leukemia effects and graft-versus-host disease, significantly inhibiting the inflammatory response of GVHD and enhancing transplantation. Anti-leukemia effects and reduce the severity of GVHD.

Benefits of technology

P.merdae strain can significantly improve the symptoms of GVHD, improve survival after transplantation, enhance the anti-leukemia effect of the transplant, reduce GVHD disease, and achieve the effect of isolating GVL and GVHD. It has the advantages of safety and clear efficacy, and provides a broader leukemia. Patient treatment prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005043254670000011
    Figure HDA0005043254670000011
  • Figure HDA0005043254670000021
    Figure HDA0005043254670000021
  • Figure HDA0005043254670000031
    Figure HDA0005043254670000031
Patent Text Reader

Abstract

The invention relates to application of parabacteroides faecalis in preparation of a medicine for separating graft anti-leukemia effect and graft-versus-host disease. Parabacteroides faecalis shows the effect of inhibiting allogeneic T cell proliferation and inflammatory response in vitro and in animal models, and the survival rate and intestinal microenvironment of GVHD mice are remarkably improved. In addition, the parabacteroides faecalis has a potential graft anti-leukemia effect. According to the invention, the parabacteroides faecalis is used as a single strain for coprophilous fungus transplantation to treat intestinal GVHD, and meanwhile, the anti-leukemia effect of the graft is enhanced, so that a wider prospect is provided for the application of the parabacteroides faecalis in leukemia patients. Compared with the traditional FMT, the parabacteroides faecalis of a single strain has the advantages of definite components, standardization, low risk and the like, and shows a good application prospect. The method has the advantages of standardization, low risk and the like, and shows good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the application of Parabacteroides faecalis, and in particular to the application of Parabacteroides faecalis in the preparation and separation of graft-versus-leukemia effect and graft-versus-host disease drugs. Background Art

[0002] Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a key method for the treatment of malignant blood tumors. It transplants hematopoietic stem cells from healthy donors to rebuild the patient's hematopoiesis and immune system, thereby achieving the goal of curing malignant blood tumors. In this process, graft-versus-leukemia effect (GvL) and graft-versus-host disease (GVHD) are two key immune responses. The GvL effect refers to the process in which donor immune cells recognize and kill malignant blood tumor cells. This effect is of great significance for preventing the recurrence of malignant blood tumors. GVHD is an immune response caused by donor immune cells attacking the recipient's normal tissues. It is a common and serious complication after allo-HSCT, which seriously affects the patient's quality of life and survival rate. GVHD is a complex and serious immune response that often involves multiple organs such as the skin, liver, and intestines. Intestinal GVHD is particularly serious, with clinical manifestations such as diarrhea, abdominal pain, and intestinal bleeding. At present, there is no standard second-line treatment for hormone-refractory intestinal GVHD. Although glucocorticoids are the first-line treatment for GVHD, about 20% of patients are ineffective and eventually develop hormone-refractory intestinal GVHD, which has a very poor prognosis and an overall survival rate of only 5-30%. However, maintaining the GvL effect while suppressing GVHD is a major challenge in clinical practice, because excessive immunosuppression may weaken the GvL effect and increase the risk of recurrence of malignant hematological tumors.

[0003] In recent years, studies have shown that intestinal flora plays an important role in the occurrence and development of GVHD and GvL. Pretreatment measures such as radiotherapy and chemotherapy after transplantation can seriously disrupt the balance of intestinal flora, reduce its diversity, and thus aggravate the symptoms of GVHD. The composition and diversity of intestinal flora directly affect the host's immune function. Healthy intestinal flora can regulate immune response, promote the repair and maintenance of intestinal barrier, and thus reduce the severity of GVHD. At the same time, changes in intestinal flora may also affect the GvL effect. Specific flora may enhance the recognition and killing ability of donor immune cells to leukemia cells through metabolites or direct immunomodulatory effects. However, there are some technical defects in the existing FMT treatment. First, the composition of the flora transplanted by FMT is complex and difficult to standardize, which affects the consistency of the treatment effect. Secondly, FMT may introduce pathogens or induce immune rejection reactions, and the previous treatment model has certain safety risks. Precision treatment of fecal microbiota transplantation with clear components is safe, effective and has a wide range of application prospects. Finally, the different sources of healthy donors for FMT will affect the efficacy of treatment, and standardized in vitro amplified strains have more consistent efficacy as therapeutic applications. Summary of the invention

[0004] The present invention aims to provide a new application of Parabacteroides merdae (P.merdae).

[0005] Specifically, the present invention provides the use of Parabacteroides faecalis P.merdae in the preparation of a drug for separating graft-versus-leukemia effect and graft-versus-host disease.

[0006] After a large number of experimental studies, the inventors found that P.merdae showed the effect of inhibiting allogeneic T cell proliferation and inflammatory response in vitro and in animal models, and significantly improved the survival rate and intestinal microenvironment of GVHD mice, indicating that the faecal parabacteroides strain has the functions of efficient repair and inhibition of inflammation, especially has a significant inhibitory effect on intestinal inflammation caused by GVHD, can effectively improve systemic GVHD symptoms, including acute GVHD and chronic GVHD, can improve post-transplantation survival rate, and enhance graft-versus-leukemia effect. Moreover, in addition, the P.merdae strain can enhance the GvL effect, reduce GVHD disease, achieve the effect of separating GVL and GVHD, and has a potential graft-versus-leukemia effect, which provides a broader prospect for its application in leukemia patients. Compared with traditional FMT, the treatment of P.merdae with a single strain has the advantages of clear ingredients, standardization, and low risk, showing good application prospects. It has the advantages of standardization and low risk, showing good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0007] Figure 1This is the identification and comparison result of 16s RNA sequence of P.merdae.

[0008] Figure 2 This is a comparison chart of P.merdae bacteria in the treatment of acute GVHD transplantation model.

[0009] Figure 3 This is a comparison chart of P.merdae bacteria in treating chronic GVHD transplantation model.

[0010] Figure 4 P.merdae improves the symptoms of intestinal GVHD by promoting the balance between Th1 and Treg, inhibiting the proliferation and activation of T cells.

[0011] Figure 5 P.merdae treatment improved the survival of A20 blood tumor transplantation model mice and reduced GVHD scores.

[0012] Figure 6 P.merdae treatment improved the survival of Baf3 hematological tumor transplantation model mice and reduced GVHD scores and tumor burden. DETAILED DESCRIPTION

[0013] 1. Isolation, preservation and in vitro culture methods of Parabacteroides faecalis

[0014] This strain was isolated and purified from the feces of healthy people. It is a Gram-negative bacterium with short rod-shaped bodies, often arranged singly or in pairs, and strictly anaerobic. It showed positive reactions in indole, hydrogen sulfide, methyl red, Voges-Proskauer, nitrate reduction and other tests; it showed negative reactions in catalase, oxidase, citrate utilization, gelatin liquefaction, urease and other tests. After 48 hours of culture on Mianyang blood agar medium, the colonies were round, smooth, with neat edges, about 1-2 mm in diameter, and milky white to light yellow.

[0015] The preparation method of Parabacteroides faecalis comprises the following steps in sequence:

[0016] (1) Separation

[0017] Take a stool sample from a healthy person, suspend the stool sample in sterile saline, and mix at a ratio of 1:10. After shaking and mixing, let it stand, take the supernatant and perform 10-fold serial dilutions, spread the dilutions on Mianyang blood agar plates, and culture anaerobically at 37°C for 48-72 hours.

[0018] (2) Purification

[0019] The initially isolated colonies were picked and purified by the plate streak method. Single colonies were picked and inoculated on new BHI agar plates, and culture and selection were repeated until a pure strain was obtained. The strain was stored on a slant made from Mianyang blood agar plates and placed in a 4°C refrigerator for later use. After high-throughput sequencing of 16S ribosomal DNA identification and comparison with the NCBI database, the strain was finally determined to be Parabacteroides merdae, see Figure 1 .

[0020] (3) Preservation method of Parabacteroides faecalis

[0021] The BHI medium for the preservation of the Parabacterium faecalis strains is composed of: 37.0 g of brain heart infusion, 10.0 g of peptone, 2.0 g of glucose, 5.0 g of sodium chloride, 2.5 g of potassium dihydrogen phosphate, 1000 ml of distilled water, and a pH value of pH 7.4. The glycerol preservation method (25% glycerol to medium ratio) is used and the temperature is minus 80 degrees.

[0022] (4) In vitro amplification and culture method of Parabacteroides faecalis

[0023] The frozen Parabacteroides faecalis strain was cultured in thioglycollate medium at 37°C for 24-48 hours to restore its activity. Then, the activated bacterial solution was transferred to deoxygenated BHI medium and shaken well, and the bacterial solution was dipped with a disposable sterile inoculation loop and streaked on a blood agar plate. The blood agar plate was placed in an anaerobic incubator and cultured anaerobically at 37°C for 48-72 hours using a deoxygenated bag. The morphology, color and size of the colonies on the plate were observed. Using fluorescent real-time quantitative polymerase chain reaction (qPCR), the purity of the bacterial flora was dynamically monitored using primer pairs F: AGGGTGCGTAGGTGGTGAT and R: TTCACCGCTACACCACGC. Thermo Fisher's PowerUp SYBR TM Green Master Mix Kit. In a 20 μL qPCR reaction system, prepare the following components: 10 μL 2X PowerUp SYBR TM Green Master Mix, 0.5 μM forward primer (F), 0.5 μM reverse primer (R), 2 ng template DNA, add deionized water to the total reaction volume. qPCR amplification conditions are as follows:

[0024] step temperature time Cycle times Pre-denaturation 95℃ 2 minutes 1 transsexual 95℃ 15 seconds 40 Annealing / Extension 60℃ 1 minute 40 Melting curve analysis 95℃ 15 seconds 1 60℃ 1 minute 1

[0025] The colony with the strongest qPCR signal on the plate was selected and inoculated into deoxygenated BHI medium for anaerobically culture, and the medium was changed by centrifugation every 48-72 hours. The number of viable bacteria was detected by flow cytometry using SYT09 and propidium iodide staining.

[0026] 2. Isolation of Parabacteroides faecalis for graft-versus-leukemia effect and graft-versus-host disease

[0027] Experimental methods:

[0028] 1. Construction of GVHD model: Balb / c (H-2d) mice and FVB (H-2q) mice were used as donors, and C57BL / 6 (H-2b) mice were used as recipients. After whole-body irradiation (800-1000 cGy), bone marrow and T cells from the donor were infused back through the tail vein to induce GVHD. In the chronic GVHD (cGVHD) model, the transplantation operation is similar to aGVHD, but the occurrence of chronic GVHD is induced by reducing the amount of initial T cell input. During the experiment, mice were randomly divided into PBS control group and P.Merdae treatment group for intervention, and the severity of GVHD was scored by symptoms such as skin, weight, hair, and activity of the recipient mice.

[0029] 2. Mesenteric lymph node bacterial culture method: Lymph nodes were aseptically isolated from the mesentery of mice and made into a suspension in PBS. The lymph nodes were evenly ground using a tissue grinder, and then the suspension was spread on an LB agar plate (purchased from Solebaugh) and cultured at 37°C for 24-48 hours. After culture, the colony forming units (CFU) on each culture plate were counted, and the number of bacterial colonies was calculated based on the dilution multiple. The results can be used to evaluate the intestinal barrier function and bacterial translocation, and then analyze the protective effect of the treatment on the intestinal barrier.

[0030] 3. HE staining to evaluate tissue pathology: The tissue is fixed in 4% paraformaldehyde, dehydrated and paraffin-embedded before sectioning. The sections are first dewaxed in xylene, then hydrated through gradient alcohol, stained with Hematoxylin for 5-10 minutes, rinsed and blued in ammonia. Then stain with Eosin for 30 seconds to 1 minute, dehydrated and transparentized, and finally sealed in neutral gum. The stained sections are observed under a microscope. Hematoxylin stains the nucleus blue, and Eosin stains the cytoplasm and matrix pink, which is used to evaluate histopathological changes.

[0031] 4. Observe the superficial surface of the eye with fluorescein sodium staining: drip 0.5% fluorescein sodium eye drops into the lower eyelid to ensure that the dye evenly covers the surface of the cornea and conjunctiva. The dye will adhere to the damaged area on the front surface of the eye. After closing the eyes for a while, use a slit lamp microscope and a blue light filter to observe. The damaged area will show green fluorescent spots or stripes, thereby evaluating the degree of damage to the cornea and conjunctiva.

[0032] 5. Tear measurement: Place a standard Schirmer test paper (purchased from Tianjin Yinuo Xinkang Medical Equipment Co., Ltd.) on the inner side of the mouse's lower eyelid for 5 minutes. The length of the test paper soaked represents the amount of tear secretion.

[0033] 6. CFSE staining and flow cytometry of donor T cells: Use magnetic bead antibodies to sort donor T cells, add 5μM concentration of CFSE to them, incubate at room temperature for 10 minutes, use serum-containing culture medium to terminate staining, and then wash the cells twice with PBS. The CFSE-labeled donor T cells are reinfused into C57 mice that have undergone radiotherapy and myeloablation through the tail vein. One week later, various tissues and organs are collected and ground into cell suspensions. The cell suspension is resuspended with PBS, and then surface antibodies pre-labeled with fluorescent dyes (such as antibodies against CD4, CD8 or other markers) are added, incubated at 4°C for 30 minutes, and protected from light. After incubation, wash the cells with PBS to remove unbound antibodies. Finally, use a flow cytometer to detect the fluorescence intensity of cell surface antibody markers and analyze the expression of specific molecules or cell populations.

[0034] 7. Tumor formation and in vivo imaging experiments of A20 and Baf3 leukemia mice: First, radiotherapy-myeloablated recipient C57 mice were used, and then donor Balb / c bone marrow cells were injected through the tail vein to reconstruct hematopoiesis. At the same time, an appropriate amount of A20 or Ba / F3 leukemia cells were injected into the recipient mice through the tail vein. During the experiment, the mice were randomly divided into PBS control group and P.Merdae treatment group for intervention. The spread of leukemia cells in the body and tumor growth were tracked in real time by IVIS and other in vivo imaging systems to evaluate the model and treatment effects.

[0035] Experimental results: After the application of this strain, in the aGVHD transplantation mouse model with C57 as donor and Balb / c as recipient, the survival rates on days 20, 30, 40, and 80 were increased by 21.0%, 44.7%, 52.0%, and 52.0%, respectively, compared with the control group. Figure 2 A and B; P<0.05). To exclude species differences, we also performed strain verification in an aGVHD transplant mouse model with FVB as donor and C57 as recipient. The results showed that the survival rates on days 20, 30, 40, and 80 were still improved by 25.6%, 42.6%, 48.0%, and 51.2% compared with the control group ( Figure 2 C; P<0.05). Pathological observation of intestinal target organs in the aGVHD model showed that the length of intestinal organs after P.Merdae treatment was significantly longer than that of the control group, indicating that organ inflammation was mild and there was no obvious contracture. The bacterial colony of mesenteric lymph nodes was measured and it was found that the number of intestinal flora invading mesenteric lymph nodes was significantly reduced after P.Merdae treatment ( Figure 2D, P.Merdae group: mean bacterial colony value 5 CFU / plate vs control group: 35 CFU / plate; P<0.05). HE pathological staining of GVHD target organ sections showed that lymphocyte infiltration in multiple target organs decreased after P.Merdae treatment, especially in the intestine, where the structure of the small intestine and colon was significantly restored ( Figure 2 E). In addition, in the cGVHD model with C57 as donor and Balb / c as recipient, P.Merdae treatment can alleviate cGVHD symptoms, with clinical symptoms reduced by 1, 2, and 3 points at 30, 40, and 50 days, respectively, compared with the control group (P<0.05). In the fundus and tear gland function tests, it was found that P.Merdae reduced the appearance of fundus neovascularization and significantly improved the secretion function of the tear gland ( Figure 3 AC, mean tear fluid content of the left and right eyes in the P.Merdae group: 2mm vs. control group: 1mm; P<0.05). The above results indicate that the strain plays an important and positive role in improving acute GVHD and chronic GVHD, and has a significant effect on improving the survival rate after transplantation. The P.Merdae bacteria treatment GVHD model was analyzed by flow cytometry, and the results showed that P.Merdae bacteria significantly inhibited the proliferation and activation of T cells, regulated the balance between Th1 cells and Treg cells, and reduced the attack of immune cells on intestinal epithelial cells ( Figure 4 ), which promoted the improvement of GVHD symptoms in recipients.

[0036] In the study of the A20 hematologic tumor mouse GVL transplantation model, it was found that the P. Merdae strain treated GVHD without affecting the GVL response ( Figure 5 ). In the study of the GVL model of Ba / f3 blood tumor mice, it was found that the survival rate at 21 days, 35 days, and 49 days was increased by 15.7%, 20.2%, and 40.8% compared with the control group, respectively, the GVHD score decreased by 1 point, 3 points, and 4 points, and the blood tumor signal decreased by 25%. These results show that the application of P.merdae strains can enhance the GvL effect and reduce GVHD disease, achieving the effect of separating GVL and GVHD ( Figure 6 ).

[0037] Those skilled in the art can refer to the content of this article and appropriately improve the process parameters. It is particularly important to point out that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in the present invention. The method and product of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

Claims

1. Application of Parabacteroides faecalis in the preparation and isolation of graft-versus-leukemia effect and graft-versus-host disease drugs.

Citation Information

Patent Citations

  • FMT performance prediction test to guide and optimize treatment management of GVHD patients

    CN115427583A

  • Application of palmitoleic acid in preparation of medicine for regulating intestinal flora after hematopoietic stem cell transplantation and improving acute graft versus host disease

    CN118593464A

  • Consortia of living bacteria useful for treatment of cancer related diseases, particularly graft versus host disease

    WO2020079021A1

Cited By

  • Application of parabacteroides faecalis in preparation of medicine for separating graft anti-leukemia effect and graft-versus-host disease

    CN120305292A